<DOC>
	<DOCNO>NCT02832063</DOCNO>
	<brief_summary>The purpose study demonstrate safety , tolerability efficacy B244 administer 12 week participant mild moderate acne vulgaris relative placebo .</brief_summary>
	<brief_title>Clinical Trial Subjects With Mild Moderate Acne Vulgaris</brief_title>
	<detailed_description>This Phase IIb/III , randomize , double blind , decentralize clinical trial evaluate safety , tolerability , efficacy B244 compare placebo treatment acne vulgaris 1.1 . Primary Objectives 1 . To evaluate safety tolerability B244 participant acne vulgaris 2 . To assess efficacy B244 participant mild moderate acne vulgaris baseline week 12 ( end treatment ) : ) Reduction inflammatory non-inflammatory lesion count ii ) IGA success 3 . Improvement patient report quality life score use Skindex-16 questionnaire participant acne vulgaris baseline week 12 1.2 . Secondary Objectives 1 . To evaluate efficacy B244 participant mild moderate acne vulgaris baseline week 2 , 4 , 8 , 16 : ) Reduction inflammatory non-inflammatory lesion count ii ) IGA success iii ) Improvement patient report quality life score use Skindex-16 questionnaire 1.3 . Exploratory Objective 1 . To evaluate facial skin microbiota participant acne vulgaris baseline , week 4 , week 8 , week 12 , week 16 B244-treated participant compare placebo : ) Skin swab take forehead , nose , cheek chin All participant ( placebo B244 ) undergo skin swab testing .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Participants eligible enrollment study must meet following criterion : 1 . Male female age 18 old 2 . Clinical diagnosis mild moderate facial acne vulgaris define : 1 . ≥5 inflammatory lesion , ; 2 . ≥10 noninflammatory lesion , ; 3 . IGA 23 3 . Willing refrain use treatment , investigational product , acne present face . This include use antibiotic treatment acne . Topical acne treatment significant measurable systemic absorption ( e.g. , benzoyl peroxide , salicylic acid ) allow treatment nonfacial acne . 4 . Willing able provide inform consent comply study protocol . 1 . Pregnant and/or lactate female 2 . Continuous plan use tan booth excessive sun exposure , opinion Investigator . 3 . Active cystic acne acne conglobata , acne fulminans , secondary acne 4 . Two active nodular lesion 5 . Treatment overthecounter topical medication treatment acne vulgaris include benzoyl peroxide , topical antiinflammatory medication , corticosteroid , αhydroxy/glycolic acid , topical probiotic include commercially available product AO+Mist face within 7 day prior baseline . 6 . Treatment systemic corticosteroid within 28 day prior baseline . 7 . Treatment systemic antibiotic systemic antiacne drug within 7 day prior baseline . 8 . Prescription topical retinoid use face within 7 day baseline ( e.g. , tretinoin , tazarotene , adapalene ) . 9 . Commencement new hormonal therapy dose change hormonal therapy within 90 day prior baseline . Dose frequency use hormonal therapy start 90 day prior baseline must remain unchanged throughout study . Hormonal therapy include , limited , estrogenic progestational agent birth control pill . 10 . Use androgen receptor blocker ( spironolactone flutamide ) 7 day prior randomization . 11 . Oral retinoid use ( e.g. , isotretinoin ) within 180 day prior baseline vitamin A supplement great 10,000 units/day within 180 day baseline . 12 . Cosmetic facial procedure ( chemical laser peel , microdermabrasion , etc . ) within 28 day first dose study . 13 . History sensitivity study medication , component thereof history drug allergy , opinion Investigator Medical Monitor , contraindicate participation . 14 . Any condition study Investigator feel would indicate participation would best interest participant . 15 . The participant previously randomize study . 16 . The participant receive investigational product within 30 day 5 halflives , whichever long prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>